Head and Neck Cancer (Nasopharynx)

    Actionable Target Abnormality Prevalence Clinical Experience with Targeted Agent
    PD-1/PD-L1 N/A N/A Pembrolizumab (anti-PD-1 antibody):
    • Phase 2: ORR 26% (12)
    Other topics in Targets by Organ Site